Duchnowska, R., Soter, K., Pogoda, K., Żubrowska, J., Grela-Wojewoda, A., Winsko-Szczęsnowicz, K., Szwiec, M., Kowalewska-Felczak, A., Danielewicz, I., Lewandowski, T., Streb, J., Szymanowski, B., Kiszka, J., Kalinka, E., Tomasik, B., Radecka, B., Litwiniuk, M. M., Łacko, A., Balata, A. K., Bieńkowski, M. (2025). Prognostic value of estrogen receptor (ER) and progesterone receptor (PR) expression levels in de novo and recurrent HR+/HER2- metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET): Real-world evidence.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e13078